{"id":"W4399394132","doi":"10.1200/jco.2024.42.16_suppl.4502","title":"Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Astellas Pharma US","keywords":"Medicine; Internal medicine; Gemcitabine; Progression-free survival; Brief Pain Inventory; Quality of life (healthcare); Cancer; Carboplatin; Hazard ratio; Chemotherapy; Gastroenterology; Randomized controlled trial; Cisplatin; Oncology; Urology; Confidence interval; Physical therapy; Chronic pain","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003856428,0.001155099,0.001333426,0.0003721405,0.0003565589,0.0007359627,0.0005956778,0.001114501,0.005917466],"category_scores_gemma":[0.002659584,0.0003704051,0.002257703,0.0004830477,0.0005607626,0.0006733413,0.0006577916,0.002265479,0.0004742253],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005808608,"about_ca_system_score_gemma":0.0007839982,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005915212,"about_ca_topic_score_gemma":0.001116208,"domain_scores_codex":[0.9981235,0.001341694,0.00008945908,0.0001514176,0.0001432502,0.000150668],"domain_scores_gemma":[0.9982645,0.0005130036,0.0006547174,0.00008271515,0.00009398095,0.0003910238],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9729268,0.003316098,0.003552512,0.0005085059,0.001646663,0.00004400309,0.00004214996,0.0009781356,0.0009057079,0.00007272742,0.001275077,0.01473164],"study_design_scores_gemma":[0.7659331,0.1926813,0.0334423,0.0001123623,0.003033912,0.0001554458,0.00005319435,0.001333845,0.0008285912,0.000289324,0.002104439,0.000032079],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.984211,0.002856576,0.0005011398,0.0004610288,0.00014418,0.003800979,0.005921873,0.00004221681,0.00206111],"genre_scores_gemma":[0.9841136,0.001228349,0.0009781183,0.0006310137,0.0001694371,0.006331536,0.005242064,0.0000156415,0.001290231],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005917466,"threshold_uncertainty_score":0.02039492,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09391004980722414,"score_gpt":0.4765821723379932,"score_spread":0.382672122530769,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}